| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers B > Headlines for Biocompatibles International plc > News item |
Biocompatibles begins trial of Doxorubicin-Eluting Bead for treatment of lung cancer
By Angela McDaniels
Seattle, Feb. 9 - Biocompatibles International plc has begun a trial of its Doxorubicin-Eluting Bead for the treatment of lung metastases or non-small cell lung cancer, according to a company news release.
The 20-patient trial is taking place at the Johann Wolfgang Goethe University in Frankfurt, Germany, and is designed to determine whether the design and pharmacokinetics of the Doxorubicin-Eluting Bead can improve the efficacy of transpulmonary chemoembolisation, a procedure whereby a chemotherapeutic agent is mixed into a slurry and injected via a catheter into the tumor site.
The endpoints are safety and efficacy measured by tumor response at six months.
Lung cancer is the cause of more than 350,000 deaths annually in the European Union and United States, according to the release. The five-year survival rate is only 15%, compared with 88% and 99% in breast cancer and prostate cancer, respectively.
"The prognosis for this group of patients is poor and we are pleased to have the opportunity to evaluate a promising new technology," lead investigator Thomas Vogl said in the release.
If the study yields positive data, Biocompatibles said it will begin a multi-center, randomized trial with survival as the primary endpoint in order to support the approval of the Doxorubicin-Eluting Bead as a treatment for lung cancer.
The Doxorubicin-Eluting Bead is approved in Europe for the treatment of malignant hypervascularized tumors.
Biocompatibles is a medical technology company based in Farnham, England, that develops drug device combination products for use in cardiology and oncology.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.